IC
CABA icon

Ikarian Capital’s Cabaletta Bio CABA Stock Holding History

Ikarian Capital’s Portfolio CABA Stock Details CABA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-200,000
Closed -$3.41M – 125
2024
Q1 		$3.41M Hold
200,000
– – 0.37% 66
2023
Q4 		$4.54M Buy
+200,000
New +$3.36M 0.43% 61

Other funds holding CABA

Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Ikarian Capital's CABA Position: Q2 2026 in Review

Ikarian Capital reduced its Cabaletta Bio (CABA) stake by 22% in Q2 2026, selling an estimated $658K and leaving 700,000 shares worth $2.18M. The position accounts for 0.23% of the portfolio, ranked #86.

Ikarian Capital first reported a position in CABA in Q1 2021 and has held it in 12 quarters since. The position peaked at $14.4M in Q3 2021. 140 funds tracked by Wall St. Rank hold CABA as of Q2 2026.

  • Ikarian Capital held 700,000 shares of Cabaletta Bio worth $2.18M as of Q2 2026.
  • Ikarian Capital sold 200,000 Cabaletta Bio shares in Q2 2026, an estimated $658K.
  • Cabaletta Bio made up 0.23% of Ikarian Capital's portfolio in Q2 2026, its #86 holding.
  • Ikarian Capital first reported a position in Cabaletta Bio in Q1 2021 and has held it in 12 quarters since.
  • Ikarian Capital's Cabaletta Bio position peaked at $14.4M in Q3 2021.
  • 140 funds tracked by Wall St. Rank held Cabaletta Bio as of Q2 2026.

Based on Ikarian Capital's 13F filing for Q2 2026, filed 14 Aug 2026.